Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations
Novel efficient vaccines are needed to control tuberculosis (TB), a major cause of morbidity and mortality worldwide. Several TB vaccine candidates are currently in clinical and preclinical development. They fall into two categories, the one of candidates designed as a replacement of the Bacille Cal...
Main Authors: | Amaya Leunda, Aline Baldo, Martine Goossens, Kris Huygen, Philippe Herman, Marta Romano |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-06-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-393X/2/2/463 |
Similar Items
-
Biosafety materials for tuberculosis treatment
by: Wei Wang, et al.
Published: (2022-08-01) -
Biosafety: The invisible armour
by: Abhiruchi Galhotra, et al.
Published: (2015-01-01) -
Treatment of Rheumatoid Arthritis with Gene Therapy Applications: Biosafety and Bioethical Considerations
by: Zinovia Tsitrouli, et al.
Published: (2021-06-01) -
Performance Test and Evaluation of Self-developed Biosafety Cage Changing Workbench
by: SU Shibo, et al.
Published: (2022-04-01) -
Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy
by: Elizabeth Robilotti, et al.
Published: (2023-09-01)